论文信息 - Abstract GS1-10: Phase III study of trastuzumab emtansine (T-DM1) vs trastuzumab as adjuvant therapy in patients with HER2-positive early breast cancer with residual invasive disease after neoadjuvant chemotherapy and HER2-targeted therapy including trastuzumab: Primary results from KATHERINE - 字舞流文

Abstract GS1-10: Phase III study of trastuzumab emtansine (T-DM1) vs trastuzumab as adjuvant therapy in patients with HER2-positive early breast cancer with residual invasive disease after neoadjuvant chemotherapy and HER2-targeted therapy including trastuzumab: Primary results from KATHERINE

A. Schneeweiss | S. Loibl | M. Untch | G. von Minckwitz | C. Jackisch | W. Jacot | P. Rastogi | M. Mano | P. Fasching | A. Redondo | H. Douthwaite | Z. Shao | M. Smitt | E. Mamounas | N. Wolmark | P. Wuelfing | C. Geyer | C. Arce-Salinas | H. Wu | C.-S. Huang | E. Rota Caremoli | D. Tesarowski | J. Crown | HH Fischer | AK Conlin | I. Wapnir | MP DiGiovanna | Lh Lam | S. Singel